Component
Human diabetic-neuropathy sural nerve morphometry
Human diabetic-neuropathy sural nerve morphometry
1 recorded relationships. Experimental role, claim status and evidence remain attached to each record.
How nutrients influence it
Every nutrient with a recorded effect on this component, credited to the nutrient that acted rather than the chapter that recorded it. Open a nutrient to see the findings and the conditions they were measured under.
Other things that act on it
Enzymes, hormones, genes, and other components with a recorded effect. These are not nutrients, so they do not count toward the arrows above. Each finding names the chapter that recorded it.
How nutrients reach it in more than one step
Chains of two or more recorded steps that end here, grouped by the nutrient they start from. Each step is a separate finding, so a chain is a route a mechanism could take, not proof that it does.
Tracing routes…
What it does
Every recorded relationship this component is part of, grouped by its role. Plain wording comes first; the technical statement follows.
What acts on it
ALCAR improved reported sural fiber-number and regenerating-cluster measurements in pooled diabetic-neuropathy trials.
Experimental context and source evidence
- evidence_access
- Indexed primary abstract/metadata only; unextracted doses, figures and methods remain unknown.
- experimental_contrast
- {"intervention": "ALCAR regimen", "comparator": "Placebo", "endpoint": "ALCAR improved reported sural fiber-number and regenerating-cluster measurements in pooled diabetic-neuropathy trials.", "effect_direction": "increase", "combination": "single", "conditions": []} Explicit extracted experimental comparison; source-derived draft.
- experimental_model
- Two 52-week placebo-controlled trials; 1,257 ITT patients; 500 or 1,000 mg three times daily.
- interpretation_status
- Source-derived curation with stated access limits; ungraded, not independent replication.
- limitations
- Limited to the recorded preparation, model, exposure and endpoint. Does not establish a human dietary deficiency, clinical benefit or unique molecular mediation.
- nutrient_topic
- Acetyl-L-carnitine collection; exact intervention and molecular form govern interpretation. · Acetyl-L-carnitine
- plain_language
- ALCAR improved reported sural fiber-number and regenerating-cluster measurements in pooled diabetic-neuropathy trials.
- primary_references
- Acetyl-L-carnitine improves pain, nerve regeneration, and vibratory perception in patients with chronic diabetic neuropathy: an analysis of two randomized placebo-controlled trials. | https://pubmed.ncbi.nlm.nih.gov/15616239/ | https://doi.org/10.2337/diacare.28.1.89
- source_locator
- Reviewed reference dpn05-biopsy; Two 52-week trials, 1,257 intention-to-treat patients; 500 or 1,000 mg three times daily. Morphometry is not an ulcer/amputation endpoint.
Acetyl-L-carnitine: detailed mechanisms of action (reviewed 6 October 2026) · lines 475–481
AI-assisted original review of primary studies and clearly identified official records. Exact primary access is stated; no independent replication is claimed. · supports · Two 52-week placebo-controlled trials; 1,257 ITT patients; 500 or 1,000 mg three times daily. · Recorded from source · Recorded from source
### dpn05-biopsy ALCAR improved reported sural fiber-number and regenerating-cluster measurements in pooled diabetic-neuropathy trials. Two 52-week trials, 1,257 intention-to-treat patients; 500 or 1,000 mg three times daily. Morphometry is not an ulcer/amputation endpoint. Model and exposure: Two 52-week placebo-controlled trials; 1,257 ITT patients; 500 or 1,000 mg three times daily. Limitations: Limited to the recorded preparation, model, exposure and endpoint. Does not establish a human dietary deficiency, clinical benefit or unique molecular mediation. Reference: Acetyl-L-carnitine improves pain, nerve regeneration, and vibratory perception in patients with chronic diabetic neuropathy: an analysis of two randomized placebo-controlled trials. | 2005 | https://pubmed.ncbi.nlm.nih.gov/15616239/ | https://doi.org/10.2337/diacare.28.1.89 | Access: Indexed primary abstract/metadata only; unextracted doses, figures and methods remain unknown.
Complete structured claim and evidence
The events it takes part in
A mechanism often involves more than two components. These are the full events, with every participant and its role.
Situations it appears in
Low-supply and faulty-machinery situations recorded in the chapters where this component plays a part.
In the sources
Preserved passages that mention this component, quoted exactly. Open one to read it in context.
Open hypotheses
Proposed ideas that involve this component. They are labeled as hypotheses and do not change any recorded statement.
This is a research prototype built from draft material. It is not medical advice, and its statements still await verification against the original studies.